|Positive WB detected in||LNCaP cells, HepG2 cells, HeLa cells|
|Western Blot (WB)||WB : 1:1000-1:6000|
|Sample-dependent, check data in validation data gallery|
66515-1-Ig targets E2F1 in WB, IP, IF, ChIP, ELISA applications and shows reactivity with Human, mouse, rat samples.
|Tested Reactivity||Human, mouse, rat|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||E2F1 fusion protein Ag17363|
|Full Name||E2F transcription factor 1|
|Calculated molecular weight||437 aa, 47 kDa|
|Observed molecular weight||55-60 kDa|
|GenBank accession number||BC050369|
|Gene ID (NCBI)||1869|
|Purification Method||Protein A purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Transcription factor E2F1 (E2F1), also known as RBBP3, is a transcription activator that binds DNA cooperatively with dp proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F-1 binds preferentially RB1 protein, in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent apoptosis. The calculated molecular weight of E2F1 is 47 kDa, but the sumoylated E2F1 is bout 55-60 kDa.
Cell Death Dis
E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway.
FEBS Open Bio
Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis.
Cell Biol Int
FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression
J Gene Med
Downregulation of lncRNA HCG11 promotes cell proliferation of oral squamous cell carcinoma through sponging miR-455-5p.
J Gene Med
Long non-coding RNA SNHG1 activates glycolysis to promote hepatocellular cancer progression through the miR-326/PKM2 axis.
Myricanol Inhibits Platelet Derived Growth Factor-BB-Induced Vascular Smooth Muscle Cells Proliferation and Migration in vitro and Intimal Hyperplasia in vivo by Targeting the Platelet-Derived Growth Factor Receptor-β and NF-κB Signaling.